BioStock: Chordate’s CSO is looking forward to the migraine results
The medtech company Chordate Medical currently has two patient studies that are in the final stages and two studies in the planning stage. BioStock contacted CSO Jan Hermansson to find out more about the studies and the company’s K.O.S technology for the treatment of migraine and rhinitis.Read the interview at biostock.se: https://www.biostock.se/en/2022/06/chordates-cso-is-looking-forward-to-the-migraine-results/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se